Status:
ENROLLING_BY_INVITATION
Effects of Different Exercises on Intrahepatic Lipid in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions:
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
This is a single-center, randomized, parallel controlled study to explore the effects of aerobic exercise, resistance exercise or aerobic combined resistance exercise on liver lipid in patients with M...
Detailed Description
This study was a single-center, randomized, parallel controlled clinical study. It conducted a 12-week exercise intervention for patients with MASLD, aiming to explore the effects of different exercis...
Eligibility Criteria
Inclusion
- Metabolic dysfunction-associated steatotic liver disease pantients with high willingness and compliance;
- Age: 18-45 years old;
- BMI: 25-40kg/m2;
- Liver MRI-PDFF \> 10%;
- Weight change \<3% within 3 months before the intervention;
- Being sedentary (≤60 minutes/week of moderate intensity exercise)
- Without diabetes, or combined with type 2 diabetes (lifestyle control and glycated hemoglobin ≤7%).
Exclusion
- Patients with a history of excessive alcohol consumption: Excessive alcohol consumption was defined as an average daily consumption of more than 20g of ethanol in women and 30g in men.
- Other types of chronic liver disease: such as viral hepatitis, cirrhosis, liver cancer, autoimmune liver disease, Wilson's disease, alpha-1 antitrypsin deficiency, hemochromatosis, drug-induced liver disease, etc.
- Combined with other metabolic diseases: such as type 1 diabetes, hyperthyroidism, hypothyroidism, cushing syndrome, etc.
- Patients with cardiovascular disease: such as uncontrolled hypertension, acute coronary syndrome, myocardial infarction, severe arrhythmia requiring medical therapy, etc.
- Patients with cerebrovascular diseases: such as cerebral hemorrhage, ischemic stroke, etc.
- Patients with the history of biliary obstruction, neuromuscular disease, skeletal deformity, severe osteoporosis, chronic kidney disease, and malignancy.
- Patients used drugs which may have potential effects on MASLD within 1 year before randomization, including PPAR agonist, SGLT2 inhibitor, GLP1 receptor agonist, insulin, etc.
- Patients with the history of bariatric surgery, major surgery within 8 weeks before randomization, etc,
- Patients were enrolled in another clinical trial for the treatment of MASLD or weight loss within 1 year before randomization.
- Pregnancy, lactation period, or women who plan to pregnant within 6 months before randomization.
- Patients with mental healthy problems requiring medication.
- Inability or unwillingness to undergo magnetic resonance imaging, including claustrophobia, implantable cardioverter defibrillators, and pacemakers.
- Patients cannot complete 12-week exercise plan due to some reasons, such as frequent business trips.
- After assessment, patients are not suitable or unable to participate in this clinical trial due to personal reasons.
Key Trial Info
Start Date :
March 9 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 20 2026
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT06994871
Start Date
March 9 2025
End Date
June 20 2026
Last Update
June 5 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China, 210008
2
Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, China